Population data suggests that
efavirenz and
nevirapine may reduce
caspofungin levels. This is in line with the known enzyme-inducing properties of these
NNRTIs.
The manufacturers say that consideration should be given to increasing the dose of
caspofungin from 50 to 70 mg daily.